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A B S T R A C T
This retrospective observational study investigated the prevalence of obesity in persons with type 2 diabetes, trends in
obesity resulting from the duration and treatment of diabetes, and treatment-related changes in HbA1c and body mass
index (BMI). Data on 1773 type 2 diabetics (802 men and 971 women) were obtained from the CroDiabNET registry. Fol-
low-up included the analysis of patients’ age, disease duration, diabetes treatment, BMI and HbA1c values. A signifi-
cantly higher rate of overweight and obesity was found in persons with type 2 diabetes as compared to the general popula-
tion. A significant decrease in BMI was observed in the groups treated by diet, and in those treated by oral hypoglycaemic
agents (p<0.05), regardless of their pharmacotherapeutic group, in contrast to a significant increase in BMI observed in
the groups treated with insulin (alone or in combination with oral hypoglycaemic agents) (p<0.05). Persons with type 2
diabetes lost weight only during the first years of the disease, while with diabetes duration and insulin treatment they re-
gained weight. A significant increase in HbA1c was observed in the groups treated with sulfonylureas (p<0.05), whereas
all other groups revealed either a significant decrease (p<0.05) or no change in HbA1c. Our findings suggest the neces-
sity of an integrated approach to managing type 2 diabetic patients that would simultaneously address both diabetes and
obesity. Good glycaemic control is imperative and diabetes treatment should not be postponed. Because of a possible con-
comitant weight gain, aggressive weight control measures should be applied concurrently in order to achieve maximum
treatment benefit.
Key words: diabetes mellitus, epidemiology, obesity, overweight, prevalence, weight gain
Introduction
Obesity has long been considered a product of the
modern life style in developed countries. Its increasing
frequency in developing countries, however, points to a
global paradox: a double burden of a still unsolved prob-
lem of malnutrition and of the epidemic of obesity and its
comorbidities such as diabetes, hypertension, cancer and
cardiovascular diseases1. Over the past decades advanced
work technology, sedentary leisure-time behaviour2, and
greater availability, lower cost and enhanced flavour of
food have led to energy imbalance. A seemingly small im-
balance between the intake and the expenditure causes a
major weight gain and is sufficient to explain the epide-
mic3,4. Obesity is the first step towards chronic disea-
ses5–7, not only increasing the risk of their onset, but also
affecting their course and determining their treatment
and prognosis8,9. Diabetes is a chronic disease closely as-
sociated with obesity, its growing prevalence in the world
being parallel to and conditioned by the global epidemic
of obesity. On the other hand, obesity is the most impor-
tant risk factor for the development of type 2 diabetes,
weight gain being estimated to be responsible for up to
90% of diabetes worldwide10.
Obesity is considered to promote insulin resistance,
although exact mechanisms are not clear11. Obese per-
sons have been known to have decreased glucose stimu-
lated insulin secretion and increased hepatic gluconeoge-
nesis12, and to be at a much greater risk of developing
diabetes13,14, the age at the onset of diabetes being ear-
lier15 and the risk rising almost exponentially with an in-
crease in body mass index. This higher risk of diabetes in
obese persons is responsible for a significantly greater
prevalence of type 2 diabetes in this population as com-
pared to the general one. Obesity influences not only the
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onset, but also the course of this type of diabetes16. Type
2 diabetic patients who have lost weight have signifi-
cantly better diabetes control17 and even their intention
to lose weight is associated with a reduced risk of all-
-cause mortality, independent of whether they actually
lose weight or not18. The multiple association between
obesity and diabetes is amplified by the fact that persons
with diabetes lose weight much harder19, the vicious cir-
cle thus being closed.
The goal of this study was to establish the prevalence
of obesity in persons with type 2 diabetes and compare it
with that in the general population. A further aim was to
assess trends in the duration and treatment of diabetes
with respect to obesity in order to enable physicians to
maximize the benefit of treatment.
Patients and Methods
To examine the association between type 2 diabetes
and body weight, body mass index (BMI) was determined
at initial (BMI 1) and final (BMI 2) examinations in 1,773
consecutive patients with type 2 diabetes (971 women
and 802 men). Annual changes in body mass index and
glycated haemoglobin A1c (D BMI; D HbA1c) were fol-
lowed for 1.5 years (median 1.58 yrs.; range 1.08–2.58 yrs.).
The subjects (median age 66 years, range 23–91 yrs.) had
diabetes for an average of 11 years (range 2–47 yrs.).
Data from outpatients regularly attending the Clinic
in 2003 were retrieved from the CroDiab NET, a software
developed to improve the quality of diabetes care and re-
cord keeping, and to simultaneously create a database for
the national diabetes registry20. Medical history, labora-
tory and physical examination data of all patients visit-
ing the outpatient department of the Vuk Vrhovac Uni-
versity Clinic are incorporated into unique electronical
medical records within the database. As the Clinic is a
Croatian referral centre for diabetes, data from patients
from all over the country were included. All participants
were Caucasians, as are >99% of the Croatian popula-
tion. For the purpose of this study last entries from 2003
and those from the first half of 2005 were included.
HbA1c was determined by an automated immunotur-
bidimetric method on an Olympus AU600 analyser (Olym-
pus Optical Co., Tokyo, Japan) using Bayer reagents
(Tarrytown, Il, USA)21. BMI was calculated as weight
(kg) divided by the square of height (m). D BMI and D
HbA1c were calculated as final minus baseline values di-
vided by the duration of the follow-up.
The study was approved by the Clinic’s Ethics Com-
mittee. An estimate of the required sample size was
made according to the published reports and recom-
mendations22–24.
Statistical methods
All statistical analyses were performed using SAS
(version 9.1.3).
Variance homogeneity was tested by Lindman’s test
prior to the analysis of correlation and between-group
differences. Normality of distribution was tested by us-
ing Shapiro-Wilks’ W test. Differences between groups
for independent variables were analyzed using Mann-
-Whitney U test (for two groups) and Kruskall-Wallis test
(for three or more groups). Wilcoxon matched pairs test
was used to determine differences between initial and fi-
nal values, while differences in the prevalence of individ-
ual conditions were tested using chi2 test. The level of
significance of correlation between variables and the cor-
relation trend were analyzed by Spearman Rank Order
Correlation Test. Statistically significant differences were
defined as p value less than 0.05 (p<0.05) in all analyses.
Results
At the beginning of the study median BMI and HbA1c
were 28.08 kg/m2 (interquartile range 25.81–30.85 kg/m2)
and 7.83% (interquartile range 6.85–9.18 %), respec-
tively. By the end of the study BMI decreased by 0.04
kg/m2 (interquartile range –0.43–0.48 kg/m2), while HbA1c
decreased by 0.21% (interquartile range –0.31–0.79 %)
on average.
Prevalence of overweight and obesity
To establish the prevalence of overweight and obesity
in the investigated population, the subjects were divided
into groups according to their BMI values (Group 1 con-
sisted of subjects with BMI<25kg/m2, Group 2 of over-
weight subjects with 25kg/m2BMI<30kg/m2, and Group
3 consisted of obese subjects with BMI30 kg/m2). Out of
the total number of studied persons, 54% (433/ 802) of
men and 45% (437/971) of women were overweight, and
25% (201/802) of men and 39% (379/971) of women were
obese. A statistically significant difference was found in
the degree of obesity between persons with type 2 diabe-
tes of both sexes and the general population of Croatia
(p<0.001)23.
Disease duration
Mean D BMI values according to the duration of dia-
betes and sex are shown in Figure 1.
Weight loss was observed in the first years from the
onset of diabetes, decreasing with time, and switching to
a weight gain later in the course of the disease until oc-
curring again approximately 20 years after the diagnosis.
D BMI increased with the duration of diabetes, showing
statistically significant positive correlation with disease
duration (p<0.001).
Treatment method
To establish possible differences among the groups as
defined by the treatment method, all subjects with type 2
diabetes were divided into 6 groups as shown in Table 1.
Statistically significant among-group differences were
observed in patients’ age and diabetes duration (p<
0.001), with the longest duration identified in the insulin
groups (i-i and iOHA-iOHA) and the oldest age in the in-
sulin (i-i and iOHA-iOHA) and sulfonylurea (s-s) groups.
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Initial BMI and HbA1c values also significantly differed
among the groups (p<0.001), with the highest BMI val-
ues observed in the biguanide (metformin) group (b-b)
and the highest HbA1c in the insulin (i-i and iOHA-
-iOHA) and sulfonylurea (s-s) groups.
A statistically significant decrease in BMI values was
found in the groups treated with diet and exercise (d-d),
and with oral hypoglycaemic agents (d-OHA, s-s, b-b)
(p<0.001) regardless of their pharmacotherapeutic group
and mechanism of action. In contrast, groups treated
with insulin alone (i-i) or combined with oral hypogly-
caemic agents (iOHA-iOHA) revealed a statistically sig-
nificant increase in BMI (p<0.001, p=0.015). As a result
of an increase in some groups and a comparable decrease
in others, diabetic population as a whole did not differ
significantly in its initial and final BMI values (p=0.472).
HbA1c values showed a statistically significant decrease
in the groups treated with diet (d-d), biguanides (metfor-
min) (b-b), insulin (i-i) and insulin + oral hypoglycaemic
agents (iOHA-iOHA) on both visits (p<0.001), but a sta-
tistically significant increase (p=0.002) in the group trea-
ted with sulfonylurea (s-s). In the group which was
treated with diet on the initial visit and with oral hypo-
glycaemic agents on the final visit (d-OHA) there was no
significant change in HbA1c (p=0.995). As the decrease
occurred in the majority of groups, diabetic population as
a whole was found to differ significantly in its initial and
final HbA1c values (p<0.001). D BMI and D HbA1c of in-
dividual groups are shown in Figure 2.
Discussion and Conclusion
The prevalence of overweight and obesity in persons
with type 2 diabetes in Croatia was found to be higher
than that in the general population23, the results being
comparable to those of the UKPDS25. Correlation be-
tween disease duration and D BMI was found to be both
positive and statistically significant. The follow-up re-
vealed a decrease in the studied patients’ BMI values
during the first years of diabetes. The decrease rate di-
minished with time, switching to an increase in BMI,
which was found to rise with longer diabetes duration. In
the patients with long-standing diabetes, however, the
decrease in BMI occurred again. These results confirm
previously published conclusions that the diagnosis of di-
abetes is preceded by an increase in body weight, and fol-
lowed by a continuous slow decrease in body weight and
BMI – a reversed V curve with a peak at diagnosis and/or
time immediately following the diagnosis (0–2 years)26.
In the patients with long-standing diabetes weight loss
could be partially explained by the participants’ older age
which is accompanied by commonly seen weight loss
caused with other chronic diseases and by loss of lean
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Fig. 1. – Mean D BMI values according to disease duration. 
Mean T Mean±0.95 Confidence Interval.
TABLE 1
BASELINE CHARACTERISTICS OF PATIENTS BY THE TREATMENT GROUPS
Group
symbol
Therapy characteristics Sample
size
Age
Disease
duration
BMI HbA1c
Initial End
d-d Diet Diet 94
65.5
(31–91)
5
(2–31)
27.97
(20.34–40.91)
6.60
(4.50–11.24)
d-OHA Diet
Oral hypoglycaemic
agents
89
62
(36–86)
5
(2–37)
28.63
(21.83–53.06)
7.55
(5.10–12.91)
s-s Sulfonylurea Sulfonylurea 352
67
(33–89)
7
(2–32)
27.74
(18.29–44.64)
8.08
(4.80–12.94)
b-b Biguanides* Biguanides* 325
61
(32–80)
7.5
(2–34)
29.76
(22.04–49.84)
7.43
(4.82–12.64)
i-i Insulin Insulin 592
68.5
(31–88)
16
(2–47)
27.22
(15.78–41.40)
8.24
(4.99–13.94)
iOHA-iOHA
Insulin + oral
hypoglycaemic agents
Insulin + oral
hypoglycaemic agents
321
68
(43–91)
14.5
(2–38)
27.99
(20.28–42.90)
8.03
(5.40–12.60)
Data are presented as medians and ranges
*metformin
mass27. An increase in the BMI of individuals treated
with insulin, and a decrease in those treated with diet
and exercise, and/or oral hypoglycaemic agents in the pe-
riod of time immediately following the diagnosis of diabe-
tes (0–2 yrs.) and 10 years later has also been reported26.
The results of the UKPDS28 have pointed to an in-
crease in body weight in both patients on insulin and in
those on sulfonylureas, whereas in our study weight gain
was observed only in insulin-treated patients. What is
more, the patients treated with sulfonylurea showed
weight loss as did those from both studies treated with
diet only or other oral hypoglycaemic agents. On the as-
sumption that this weight loss could be attributed to a
too long insistence on sulfonylurea treatment despite the
unsatisfactory diabetes regulation we analyzed HbA1c
changes in the investigated groups and found an increase
in the patients treated with sulfonylurea as opposed to a
decrease or lack of changes observed in other studied
groups. As this was an observational study based on data
collected from daily practice, decisions about treatment
changes were made relying on recommendations, and
not strict protocols as is the case in clinical trials such as
UKPDS. Previous observational studies have reported
diabetes duration and baseline HbA1c values to be pre-
dictors of poor glycaemic control; therefore, we analysed
these parameters in our study groups29. Both groups
treated with oral hypoglycaemic agents throughout the
study period (b-b and s-s) had comparable disease dura-
tion, whereas patients treated with sulfonylurea (s-s)
had higher baseline HbA1c values than the patients
treated with biguanides (b-b), although they were above
the target ones in the majority of patients from both
groups. Nevertheless, deterioration in glycaemic control
was observed in the sulfonylurea group (s-s) and not in
the biguanide group (b-b). The analysis of other potential
reasons for clinical inertia such as the number of medica-
tions, time since last HbA1c measurement and ethnicity
showed that they were comparable in both groups trea-
ted with oral hypoglycaemic agents throughout the study
period (b-b and s-s)30–32. Although there can also be other
reasons for clinical inertia, the fact that in Croatia at the
time of the study sulfonylurea treatment preceded the
introduction of insulin led us to assume that the underly-
ing fear of weight gain could also be responsible for the
results obtained in this study and for their divergence
from those obtained in the UKPDS28. Weight gain in in-
sulin-treated patients is caused in part by the metabolic
recovery which leads to a decreased glucose excretion via
urine. Increase in the basal metabolism conditioned by
weight gain is annulled by its simultaneous decrease
against better glycaemic control and reduced demand for
glucose production33. According to the results of the Dia-
betes Intervention Study (DIS)34, patients with stable
body weight experience statistically significantly less car-
diovascular events than those who gain weight over a
10-yr period. On the other hand, the results of the
UKPDS study28 have shown that intensified glycaemic
control reduces the risk of the development of micro-
vascular complications, but significantly increases wei-
ght gain. Practitioners are thus faced with the dilemma
of whether to intensify the treatment likely to cause
weight gain with all its consequences or insist on current
treatment and try to motivate patients to improve their
adherence to diet.
Although starting insulin therapy can nowadays be
delayed with the use of new classes of hypoglycaemic
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Fig. 2. Boxplot diagram of the differences in BMI and HbA1c according to the type of treatment.  Median 25%–75% Min-Max * Ab-
breviations: type of treatment=initial-end; i-i=insulin-insulin; s-s=sulfonylurea-sulfonylurea; b-b=biguanides-biguanides; d-OHA=
diet-oral hypoglycaemic agents; iOHA-iOHA=insulin + oral hypoglycaemic agents-insulin + oral hypoglycaemic agents; d-d=diet-diet.
agents, the dilemma is just postponed and has to be tack-
led at some time or other35. When good metabolic control
and target values of cardiovascular risk factors are ac-
hieved in only a minority of patients with diabetes36,37,
postponing a more aggressive treatment of diabetes is
not a solution; rather, it should be accompanied by mea-
sures equally addressing obesity. Good glycaemic control
must be achieved, whilst simultaneously striving to main-
tain body weight38,39.
Type 2 diabetic patients were found to be more obese
than the general population, gaining weight with disease
duration and insulin treatment. In order to reconcile as-
piration to as good glycaemic control as possible with
that to a stable body weight due to their respective ef-
fects on the development of complications, both factors
should be considered when deciding on the method of
treatment40. To avoid intensifying therapy aimed at im-
proving glycaemic control is certainly not the solution.
Our findings suggest the necessity of an integrated
approach to managing type 2 diabetic patients that would
simultaneously address both diabetes and obesity in-
stead of treating them separately. A good insight into dia-
betic patients’ body weight pattern increases the aware-
ness of critical points and thence enables physicians to
maximize the benefit of treatment.
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PRETILOST U [E]ERNOJ BOLESTI TIPA 2: PREVALENCIJA, TRENDOVI U LIJE^ENJU I
DILEME
S A @ E T A K
Ovo retrospektivno opa`ajno istra`ivanje ispitivalo je prevalenciju pretilosti kod osoba sa {e}ernom bole{}u tipa 2,
trendove pretilosti proiza{le iz trajanja i lije~enja {e}erne bolesti te promjene HbA1c i indeksa tjelesne mase (ITM)
uzrokovane lije~enjem. Podaci o 1773 bolesnika sa {e}ernom bole{}u tipa 2 (802 mu{karca i 971 `ene) dobiveni su iz
registra CroDiabNET, a pratilo se `ivotnu dob bolesnika, trajanje bolesti, lije~enje {e}erne bolesti, ITM i HbA1c. Preko-
mjerna te`ina i pretilost bile su zna~ajno ve}e kod osoba sa {e}ernom bole{}u tipa 2 nego u op}oj populaciji. Skupine
lije~ene dijetom i oralnim hipoglikemicima bez obzira na farmakoterapijsku skupinu zna~ajno su snizile ITM (p<0,05),
za razliku od skupina lije~enih inzulinom (samim ili u kombinaciji s oralnim hipoglikemicima) kod kojih je do{lo do
porasta ITM-a (p<0,05). Bolesnici sa {e}ernom bole{}u tipa 2 izgubili su na te`ini samo tijekom prvih nekoliko godina
od nastupa bolesti, dok je s trajanjem bolesti i inzulinskom terapijom ponovno do{lo do porasta te`ine. HbA1c se zna-
~ajno pove}ao u skupinama lije~enima sulfonilurejom (p<0,05), dok se u svim drugim skupinama ili zna~ajno snizio
(p<0,05) ili ostao jednak. Na{i rezultati ukazuju na potrebu integriranog pristupa lije~enju bolesnika sa {e}ernom
bole{}u tipa 2 koji bi se istovremeno bavio i {e}ernom bole{}u i pretilo{}u. Dobra regulacija glikemije je nu`na, stoga se
lije~enje {e}erne bolesti ne smije odga|ati. Radi mogu}eg prate}eg porasta tjelesne te`ine potrebno je primijeniti poja-
~ane mjere njene kontrole kako bi se postigla najve}a mogu}a korist lije~enja.
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